Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy
Journal of Labelled Compounds and Radiopharmaceuticals · 2024
DOI: 10.1002/jlcr.4124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Xingguo Hou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radio…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Immunoconjugates. Die Arbeit nennt 116 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint therapy has emerged as an effective treatment option for various types of cancers. Key immune checkpoint molecules, such as cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death protein 1 (PD‐1), and lymphocyte activation gene 3 (LAG‐3), have become pivotal targets in cancer immunotherapy. Antibodies designed to inhibit these molecules have demonstrated significant clinical efficacy. Nevertheless, the ability to monitor changes in the immune status of tumors and predict treatment response remains limited. Conventional methods, such as assessing lymphocytes in peripheral blood or conducting tumor biopsies, are inadequate for providing real‐time, spatial information about T‐cell distributions within heterogeneous tumors. Positron emission tomography (PET) using T‐cell specific probes represents a promising and noninvasive approach to monitor both systemic and intratumoral immune changes during treatment. This technique holds substantial clinical significance and potential utility. In this paper, we review the applications of PET probes that target immune cells in molecular imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Key Laboratory of Car…
- Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, China.
- Guizhou University School of Medicine, Guiyang, Guizhou, China.
Zitieren
APA
Hou, X., Kong, X., Yao, Y., Liu, S., Ren, Y., Hu, M., Wang, Z., Zhu, H., & Yang, Z. (2024). Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4124
Vancouver
Hou X, Kong X, Yao Y, Liu S, Ren Y, Hu M, et al. Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4124
BibTeX
@article{Hou2024,
author = {Hou, Xingguo and Kong, Xiangxing and Yao, Yuan and Liu, Song and Ren, Ya'nan and Hu, Muye and Wang, Zilei and Zhu, Hua and Yang, Zhi},
title = {Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2024},
doi = {10.1002/jlcr.4124}
}
EUVIMED